Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

A New Venue of TNF Targeting.

Steeland S, Libert C, Vandenbroucke RE.

Int J Mol Sci. 2018 May 11;19(5). pii: E1442. doi: 10.3390/ijms19051442. Review.

2.

Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease.

Steeland S, Gorlé N, Vandendriessche C, Balusu S, Brkic M, Van Cauwenberghe C, Van Imschoot G, Van Wonterghem E, De Rycke R, Kremer A, Lippens S, Stopa E, Johanson CE, Libert C, Vandenbroucke RE.

EMBO Mol Med. 2018 Apr;10(4). pii: e8300. doi: 10.15252/emmm.201708300.

3.

Simultaneous Inhibition of Tumor Necrosis Factor Receptor 1 and Matrix Metalloproteinase 8 Completely Protects Against Acute Inflammation and Sepsis.

Steeland S, Van Ryckeghem S, Vandewalle J, Ballegeer M, Van Wonterghem E, Eggermont M, Decruyenaere J, De Bus L, Libert C, Vandenbroucke RE.

Crit Care Med. 2018 Jan;46(1):e67-e75. doi: 10.1097/CCM.0000000000002813.

PMID:
29095202
4.

TNFR1 inhibition with a Nanobody protects against EAE development in mice.

Steeland S, Van Ryckeghem S, Van Imschoot G, De Rycke R, Toussaint W, Vanhoutte L, Vanhove C, De Vos F, Vandenbroucke RE, Libert C.

Sci Rep. 2017 Oct 20;7(1):13646. doi: 10.1038/s41598-017-13984-y.

5.

Efficient analysis of mouse genome sequences reveal many nonsense variants.

Steeland S, Timmermans S, Van Ryckeghem S, Hulpiau P, Saeys Y, Van Montagu M, Vandenbroucke RE, Libert C.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):5670-5. doi: 10.1073/pnas.1605076113. Epub 2016 May 4.

6.

Nanobodies as therapeutics: big opportunities for small antibodies.

Steeland S, Vandenbroucke RE, Libert C.

Drug Discov Today. 2016 Jul;21(7):1076-113. doi: 10.1016/j.drudis.2016.04.003. Epub 2016 Apr 11. Review.

PMID:
27080147
7.

Topical imiquimod yields systemic effects due to unintended oral uptake.

Grine L, Steeland S, Van Ryckeghem S, Ballegeer M, Lienenklaus S, Weiss S, Sanders NN, Vandenbroucke RE, Libert C.

Sci Rep. 2016 Jan 28;6:20134. doi: 10.1038/srep20134.

8.

Development and Validation of a Small Single-domain Antibody That Effectively Inhibits Matrix Metalloproteinase 8.

Demeestere D, Dejonckheere E, Steeland S, Hulpiau P, Haustraete J, Devoogdt N, Wichert R, Becker-Pauly C, Van Wonterghem E, Dewaele S, Van Imschoot G, Aerts J, Arckens L, Saeys Y, Libert C, Vandenbroucke RE.

Mol Ther. 2016 May;24(5):890-902. doi: 10.1038/mt.2016.2. Epub 2016 Jan 18.

9.

Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1.

Puimège L, Van Hauwermeiren F, Steeland S, Van Ryckeghem S, Vandewalle J, Lodens S, Dejager L, Vandevyver S, Staelens J, Timmermans S, Vandenbroucke RE, Libert C.

EMBO Mol Med. 2015 Aug;7(8):1004-17. doi: 10.15252/emmm.201405010.

10.

Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.

Steeland S, Puimège L, Vandenbroucke RE, Van Hauwermeiren F, Haustraete J, Devoogdt N, Hulpiau P, Leroux-Roels G, Laukens D, Meuleman P, De Vos M, Libert C.

J Biol Chem. 2015 Feb 13;290(7):4022-37. doi: 10.1074/jbc.M114.617787. Epub 2014 Dec 23.

Supplemental Content

Loading ...
Support Center